Fragments in the Clinic: VVD-214

Key Takeaways

• Vinyl sulfone warhead gave reactivity comparable to osimertinib but acceptable
• Adding methyl group (2a) improved stability and sub‑micromolar cellular potency
• tert‑butyl cyclopentyl replacement (5d) enabled in‑vivo tumor inhibition
• VVD‑214 showed oral bioavailability across mouse, rat, dog, and monkey
• High 24‑hour target engagement predicted tumor growth inhibition

Pulse Analysis

The WRN helicase, a key regulator of DNA repair, has emerged as a high‑value oncology target, yet only a handful of inhibitors have entered the clinic. Vividion’s approach began with a covalent fragment that bound C727 via a vinyl‑sulfone warhead, a motif rarely seen in approved drugs. Early chemoproteomic screens highlighted the fragment’s ability to cooperate with cellular ATP, steering the team toward compounds that maintain potency in the high‑ATP environment of tumor cells.

Optimization proceeded through pragmatic, data‑driven iterations. A simple methyl addition (compound 2a) curbed glutathione reactivity while sharpening cellular activity, and swapping the cyclopentyl ring for a bulkier tert‑butyl group (5d) unlocked in‑vivo efficacy in mouse xenograft models. Crucially, mass‑spectrometry revealed that once bound, the inhibitor remained on WRN for 24 hours, a kinetic advantage that correlated directly with tumor growth inhibition. The final candidate, VVD‑214, achieved oral bioavailability and consistent pharmacokinetics in rodents, dogs, and non‑human primates, positioning it for first‑in‑human trials.

Beyond the molecule itself, VVD‑214 underscores a broader shift in drug discovery. Covalent fragments, traditionally viewed as high‑risk due to off‑target reactivity, can be refined into selective, drug‑like agents when reactivity is paired with structural insight and robust target‑engagement assays. With competing non‑covalent WRN inhibitors falling out of development, VVD‑214 and its sister covalent candidate MOMA‑341 illustrate how covalent chemistry can outpace conventional approaches, offering a compelling pathway for future oncology pipelines.